Is the routine use of typhoid conjugate vaccines (TCVs) a cost-effective solution for countries? Should countries apply for TCV support from Gavi, the Vaccine Alliance? How should TCVs be introduced?
For most countries with a substantial typhoid burden, TCVs are cost-effective, but these questions are unique to every country and depend on several factors. To help decision-makers determine the best strategy for their country, TyVAC researchers conducted a health economic evaluation modeling different variables and their predicted effect on the costs, benefits, and cost-effectiveness of TCV. The results can be used to inform national decision-making for the introduction of TCVs.
Select your dataset
Launching will expand to maximize the browsing experience.
- World Overview – Explore an overview of predicted cost-effectiveness and vaccine impact modelling results for the 54 Gavi-eligible countries included in the analysis.
- Select a Country – Select a country from the map to see country-specific cost-effectiveness results, impact on disease burden, estimated vaccination costs, key input used and key drivers of the cost-effectiveness results. Adjust the inputs with the sliders to explore how the results might change according to different values.*
* NOTE: For conjecture only; model input adjustments outside of published assumptions are not supported by evidence and any adjusted results- have not been corroborated by the researchers or TyVAC.